Thermosome’s collaboration partner Philips publishes pre-clinical data of MR-HIFU mediated TSL-based drug delivery in PNAS

Researchers from Philips Research, Eindhoven University of Technology (The Netherlands) and University Hospital of Cologne (Germany) have published a joint scientific paper in the Proceedings of the National Academy of Science (PNAS), one of the world’s most prestigious scientific journals. The paper covers the use of MR-guided high intensity focused ultrasound (MR-HIFU) induced heating to locally release cancer drugs from temperature sensitive liposomes (TSL) followed by thermal destruction of tumor tissue. It describes how HIFU therapy, guided by MR imaging and used in conjunction with drug-loaded TSLs, could be used to improve cancer treatment efficacy without adding additional toxicity. The clinical translation of the MR-HIFU approach described in the PNAS paper using the Philips Sonalleve HIFU platform and the most promising TSL technology – Thermosome’s lead drug candidate derived from its DPPG2-TSL technology platform – will be further explored in the German BMBF project TSL-LIFU. Beside Thermosome and Philips, the University Hospital of Cologne and University Hospital of Munich are partners of this project, which is funded by the German Ministry of Education and Research (BMBF) with a total grant volume of approximately €4.2m.

Read Philips’ press release

Read the PNAS paper

  • On 16. Juni 2017